Endogenous opioid peptides (enkephalins, dynorphins, β-endorphin) show distinct pharmacological profiles across OPRM1 7TM C-terminal splice variants, with different binding, G-protein activation, and biased signaling patterns.
Biased signalingendogenous opioid peptides show different β-arrestin2 vs. G-protein activation across OPRM1 splice variants
What the researchers found
Endogenous opioid peptides show variant-specific pharmacological profiles across OPRM1 7TM C-terminal splice variants, with distinct patterns of receptor binding, G protein activation, and β-arrestin2 recruitment indicating biased signaling.
Why it matters
Understanding how natural opioid peptides signal differently through receptor variants could reveal why some pathways produce pain relief without addiction, potentially guiding the development of safer opioid alternatives.
The numbers in context
Three endogenous opioid families; extensive OPRM1 splice variants; differential interactions affecting pain, reward, emotion.
How the study worked
Review of pharmacological studies examining endogenous opioid peptide interactions with mouse, rat, and human OPRM1 7TM C-terminal variants. Covers binding affinity, G protein activation, β-arrestin2 recruitment, and biased signaling.
Who was studied
Endogenous opioid peptide and mu opioid receptor research across molecular, cellular, and animal studies
What this study cannot tell us
Review of primarily in vitro pharmacological data. Translation of receptor-level signaling differences to in vivo analgesic and addictive effects is complex. Species differences between mouse, rat, and human variants add complexity.
How to read the evidence
Comprehensive review of in vitro pharmacological studies across species. Provides important mechanistic framework but clinical translation of biased signaling concepts is still evolving.
When this study was published
Published in 2021. Biased agonism at opioid receptors remains a major focus of analgesic drug development.
The bigger picture
The opioid crisis has driven intense interest in understanding opioid receptor biology. The body's own opioid peptides provide pain relief without the devastating addiction seen with synthetic opioids — understanding why could be the key to developing safer pain medications.
Questions still open
- Can biased agonism at specific OPRM1 splice variants be exploited to develop non-addictive analgesics?
- Which splice variants are most relevant to clinical pain and addiction pathways?
- Could endogenous opioid peptide-mimetic drugs provide pain relief without respiratory depression?
Common questions
What are endogenous opioid peptides?
What is biased signaling?
Read the original research
Endogenous Opioid Peptides and Alternatively Spliced Mu Opioid Receptor Seven Transmembrane Carboxyl-Terminal Variants.
International journal of molecular sciences, 22(7)
Citation
Abrimian, Anna; Kraft, Tamar; Pan, Ying-Xian. (2021). Endogenous Opioid Peptides and Alternatively Spliced Mu Opioid Receptor Seven Transmembrane Carboxyl-Terminal Variants.. International journal of molecular sciences, 22(7). https://doi.org/10.3390/ijms22073779